Inbiomotion is a science-driven company founded in 2010 with a mission to improve the risk of relapse and overall survival for breast cancer patients. As a spin-out of IRB Barcelona and ICREA research labs, they combine clinical and technology innovation to benefit patients in precision medicine. Their vision is to be a global leader in developing and applying biomarker tools that prevent cancer recurrence.

Inbiomotion identifies promising scientific laboratory results and makes them available for clinical use, focusing on personalized adjuvant therapy for breast cancer. They have a strong board of directors and management team, including experts in scientific and clinical advisory boards such as Prof Rob E. Coleman, Prof Dan F.

Hayes, Prof Andrew Tutt, and Prof Joan Albanell. These esteemed professionals bring expertise in bone oncology, breast cancer, clinical cancer research, clinical trials, and personalized medicine. The company has received investment from Alta Life Science, Fundació Vila Casas, Ysios Capital, and Caixa Capital Risc.

Inbiomotion is located in Barcelona, Spain, and is committed to advancing cancer research and improving patient outcomes